Literature DB >> 12774774

Renal involvement in Anderson-Fabry disease.

Adalberto Sessa1, Mietta Meroni, Graziana Battini, Marco Righetti, Alessia Maglio, Antonella Tosoni, Manuela Nebuloni, Gianluca Vago, Ferdinando Giordano.   

Abstract

Anderson-Fabry disease (AFd) is a rare X-linked lisosomal storage disorder of glycosphingolipid (GL) metabolism, caused by a deficiency of the activity of alpha-galactosidase A (alpha-gal A). The progressive accumulation of GL in tissues results in the clinical manifestations of the disease, that are more evident in hemizygous males, and include characteristic skin lesions (angiokeratomas), neurological symptoms (acroparesthesia), ocular features (cornea verticillata), cardiac involvement (left ventricular enlargement, conduction abnormalities), cerebrovascular manifestations (thromboses, hemorrhage, etc.), and kidney involvement with progression to end-stage renal failure (ESRF). ESRF is a common manifestation in hemizygous males (3rd-5th decade) and death occurs around the 5th decade of life because of severe cardiac and/or cerebrovascular complications. Heterozygous females have an attenuated form of this systemic disease. In the kidney, accumulation of GL occurs in the endothelial cells of every vessel, in the epithelial cells of every tubular segment, and in all kinds of glomerular cells. The broad spectrum of renal lesions is a pathophysiological continuum with progressive impairment in the renal function related to continuous intracellular deposition of GL. Electron microscopic study of renal biopsies shows typical osmiophilic inclusion bodies in the cytoplasm of all kind of renal cells, characterized by concentric lamellation of clear and dark layers (35-50 A of periodicity). ESRF is treated by dialysis and kidney transplantation: neither treatment modifies the progression of the cardiovascular and cerebrovascular lesions due to progressive GL deposition. The outcome of kidney transplantation seems to be similar to that found in other non-diabetic patients, but the survival rate on dialysis is lower than in patients with other causes of ESRF. Nowadays, treatment with enzyme replacement infusion with purified alpha-Gal A, produced by a genetically engineered human cell line or Chinese hamster ovocytes, seems to be effective and safe.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12774774

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  8 in total

1.  Fabry disease and nephrogenic diabetes insipidus.

Authors:  Philip Wornell; Sarah Dyack; John Crocker; Weiming Yu; Philip Acott
Journal:  Pediatr Nephrol       Date:  2006-05-24       Impact factor: 3.714

2.  Systems biology of the autophagy-lysosomal pathway.

Authors:  Anil G Jegga; Lonnie Schneider; Xiaosen Ouyang; Jianhua Zhang
Journal:  Autophagy       Date:  2011-05-01       Impact factor: 16.016

3.  Significance of screening for Fabry disease among male dialysis patients.

Authors:  Mayuri Ichinose; Masaaki Nakayama; Toya Ohashi; Yasunori Utsunomiya; Masahisa Kobayashi; Yoshikatsu Eto
Journal:  Clin Exp Nephrol       Date:  2005-09       Impact factor: 2.801

4.  Immunohistochemical diagnosis of Fabry nephropathy and localisation of globotriaosylceramide deposits in paraffin-embedded kidney tissue sections.

Authors:  Carmen Valbuena; Dina Leitão; Fátima Carneiro; João Paulo Oliveira
Journal:  Virchows Arch       Date:  2011-12-29       Impact factor: 4.064

5.  Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.

Authors:  John Marshall; Karen M Ashe; Dinesh Bangari; KerryAnne McEachern; Wei-Lien Chuang; Joshua Pacheco; Diane P Copeland; Robert J Desnick; James A Shayman; Ronald K Scheule; Seng H Cheng
Journal:  PLoS One       Date:  2010-11-24       Impact factor: 3.240

6.  Kidney biopsy findings in heterozygous Fabry disease females with early nephropathy.

Authors:  Carmen Valbuena; Elísio Carvalho; Manuela Bustorff; Mariana Ganhão; Sandra Relvas; Rosete Nogueira; Fátima Carneiro; João Paulo Oliveira
Journal:  Virchows Arch       Date:  2008-09-04       Impact factor: 4.064

7.  Implementation of high-throughput screening for Fabry disease in Toronto dialysis patients.

Authors:  Vanessa I Rasaiah; John P Underwood; Dimitrios G Oreopoulos; Jeffrey A Medin
Journal:  NDT Plus       Date:  2008-02-14

8.  Angiokeratoma Corporis Diffusum: An Uncommon Case with Suspected Anderson Fabry Disease.

Authors:  Priyanka Vadher; Pooja Agarwal; Amit Mistry; Krishna Gajjar; Nalini Bansal; Sabha Neazee
Journal:  Indian Dermatol Online J       Date:  2020-03-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.